INDEX INTERNATIONAL COLLABORATIVE TRIALS 2) OBSERVATIONAL STUDIES AND PHASE II TRIALS 3) CLINICAL PRACTICE GUIDELINES AND REVIEWS

Transcription

1

2 INDEX 1) INTERNATIONAL COLLABORATIVE TRIALS 2) OBSERVATIONAL STUDIES AND PHASE II TRIALS 3) CLINICAL PRACTICE GUIDELINES AND REVIEWS 4) TRANSLATIONAL STUDIES FROM GEM AND ASSOCIATES

3 INTERNATIONAL COLLABORATIVE TRIALS

4

5 Hauschild. Lancet. 2012

6

7

8 Grob et al. Annals of Oncology 2014

9 Hamid. Cancer. 2014

10 OBSERVATIONAL STUDIES AND PHASE II TRIALS

11

12 ASCO 2012 SPANISH MELANOMA GROUP (GEM) EXPERIENCE WITH IPILIMUMAB IN THE EXPANDED ACCESS PROGRAMME (EAP)

13 ESMO 2012

14

15 SEOM 2014 SEOM Oct 2014

16

17

18 Phase II study evaluating Ipilimumab as a single agent in the firstline treatment of adult patients with metastatic uveal melanoma (MUM): The GEM-1 trial. (1) Piulats JM, (1) Ochoa-de-Olza M, (2) Codes M, (3) Lopez-Martin JA, (4) Berrocal A, (1) Garcia M, (5) Gurpide A, (3) Homet B, (5) Martin-Algarra S. (1) Institut Ctatalà d Oncologia de l Hospitalet del Llobregat. Barcelona. (2) Hospital Virgen de la Macarena. Sevilla. (3) Hospital 12 de Octubre. Madrid. (4) Hospital General de Valencia. Valencia. (5) Clínica Universitaria de Navarra. Pamplona.

19

20 CLINICAL PRACTICE GUIDELINES AND REVIEWS

21 The Oncologist 2010;15:416-27

22 Clin Trans Oncol. 2011

23 Clin Trans Oncol. 2012

24 Clin Trans Oncol. 2014

25 Am J Ther Jun 9. Melanoma Early Detection and Awareness: How Countries Developing Melanoma Awareness Programs Could Benefit From MelanomaProficient Countries. Wainstein A1, Algarra SM, Algarra SM, Bastholt L, Algarra SM, Bastholt L, Cinat G, Algarra SM, Bastholt L, Cinat G, Demidov L, Algarra SM, Bastholt L, Cinat G, Demidov L, Grob JJ, Algarra SM, Bastholt L, Cinat G, Demidov L, Grob JJ, Guo J, Algarra SM, Bastholt L, Cinat G, Am J Ther. 9.Treatment Demidov L,12014 Grob Jan JJ, Guo J, HerseyAlgorithms P, EspinosainE,Stage IV Melanoma. Espinosa Grob JJ, Grob JJ, Dummer R, Grob J, JJ, Dummer R, Rutkowski P, Grob JJ, SchachterEJ,, Schachter J, Whitaker D, Schachter Dummer P, Robert C, Grob JJ, Whitaker R, D, Rutkowski Quirt I, Schachter J, Whitaker D, Dummer Quirt I, R, Rutkowski P, Robert C, Gogas H, Grob JJ,A,Dummer R, J, Rutkowski Gogas H, Kefford R, Grob JJ, Dummer Hauschild Schachter WhitakerP, D,Robert Quirt I,C, Hauschild R, Rutkowski P. P, Robert C, Gogas H, Kefford R, Eggermont AM, Grob JJ, Dummer R, A, Rutkowski Am J Ther. P, 2013 Oct 31.Side Effects and R, Toxicities of Targeted Therapies Stage Rutkowski Robert C, Gogas H, Kefford Eggermont AM, Martin Algarra S,inGrob JJ, 1 IV Melanoma. Ascierto P, PARobert, Bastholt L, Bastholt L, Hersey P, BastholtAM, L, Hersey P, Cinat Dummer R, Rutkowski C, Gogas H, Kefford R, Eggermont Martin Algarra G, L, A, Hersey G, Eggermont AM,P,Bastholt G,R, S, Bastholt Hauschild Grob P, JJ,Cinat Dummer R, Rutkowski Robert L, C,Hersey Gogas P, H, Cinat Kefford Eggermont A, Bastholt L, Hersey P, Cinat G, Eggermont AM, Hauschild EggermontAM, AM,Hauschild Martin Algarra S, Hauschild A, Schadendorf D. Am J Ther Oct 30.L,Who Benefits Most From Adjuvant InterferonA, Treatment A, Espinosa E, Bastholt Hersey P, Cinat G, Eggermont AM, Hauschild Espinosa for E, Melanoma? Robert C. Gogas H1, Abali H, Abali H, Ascierto PA, Abali H, Ascierto PA, Demidov L, Abali H, Ascierto PA, Demidov L, Pehamberger H, Abali H, Ascierto PA, Demidov L, Pehamberger H, Robert C, Abali H, Ascierto PA, Demidov L, Pehamberger H, Robert C, Schachter J, Abali H, Ascierto PA, Demidov L, Pehamberger H, Robert C, Schachter J, Eggermont AM,

26 TRANSLATIONAL STUDIES

27

28

29 Mol Cancer Ther November ; C41

30

31

32 CONCLUSIONS AND FUTURE DIRECTIONS GEM: RELEVANT INTERNATIONAL ROLE MULTIDISCIPLINARY AND TRANSLATIONAL APPROACH ACTIVE YOUNG COLLABORATIVE GROUP FUTURE: COLLABORATIVE CLINICAL TRIALS WITH TRANSLATIONAL SUBSTUDIES INCLUDED POTENTIATE INTERNATIONAL COOPERATION

33